Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
1.080
+0.020 (1.89%)
Aug 13, 2025, 4:00 PM - Market closed
Cytosorbents Revenue
Cytosorbents had revenue of $9.62M in the quarter ending June 30, 2025, with 8.76% growth. This brings the company's revenue in the last twelve months to $36.11M, up 20.18% year-over-year. In the year 2024, Cytosorbents had annual revenue of $35.59M with 14.51% growth.
Revenue (ttm)
$36.11M
Revenue Growth
+20.18%
P/S Ratio
1.74
Revenue / Employee
$242,332
Employees
149
Market Cap
67.78M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 35.59M | 4.51M | 14.51% |
| Dec 31, 2023 | 31.08M | -3.60M | -10.39% |
| Dec 31, 2022 | 34.69M | -8.48M | -19.64% |
| Dec 31, 2021 | 43.17M | 2.16M | 5.27% |
| Dec 31, 2020 | 41.00M | 16.06M | 64.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CTSO News
- 5 days ago - Cytosorbents Corporation (CTSO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update - PRNewsWire
- 14 days ago - CytoSorbents Leads a New Era in Sepsis Treatment - PRNewsWire
- 16 days ago - CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights - PRNewsWire
- 6 weeks ago - CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR - PRNewsWire
- 7 weeks ago - CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR - PRNewsWire
- 2 months ago - CytoSorbents to Participate at the Jefferies Global Healthcare Conference - PRNewsWire
- 2 months ago - CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025 - PRNewsWire